» Articles » PMID: 22237560

Phenotypic and Genotypic Variability in Alpers Syndrome

Overview
Specialty Pediatrics
Date 2012 Jan 13
PMID 22237560
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Alpers syndrome is one of the most common phenotypes of mitochondrial disorders in early childhood and has been associated with pathogenic mutations in POLG1.

Aims: To investigate the phenotypic-genotypic correlations in Alpers syndrome and to identify potential differences among patients with Alpers syndrome with or without pathogenic POLG1 mutations.

Methods: Patients with the phenotype of Alpers syndrome who were referred to our pediatric hospital during 1984-2007 and were diagnosed with mitochondrial encephalomyopathy underwent further biochemical, morphological and genetic investigations.

Results: A total of 19 patients were included in the study, of whom six had pathogenic POLG1 mutations including a novel mutation (c.907 G>A, p.Gly303Arg). Complete mtDNA sequencing in the subgroup without POLG1 mutations showed 5 novel and 5 very rare mtDNA variants considered as rare polymorphisms. Compared to POLG1(-) patients, the POLG1(+) patients more frequently had seizures at onset, which often became refractory. Ataxia and stroke-like episodes were much more common, while microcephaly and spasticity were encountered almost solely in the POLG1(-) group. Hepatic and ophthalmological involvement developed in 79% and 88% of patients, respectively. Most of the patients in both groups had predominant deficiency of complex I. In addition to the major degenerative changes in the cerebral cortex, the basal ganglia, thalamus and white matter were also involved to variable extent.

Conclusion: Alpers syndrome is a heterogeneous syndrome that should be considered in patients with early-onset progressive cortical encephalopathy regardless of liver involvement. The phenotype is different depending on the presence or absence of POLG1 mutations.

Citing Articles

Presentation, Treatment, and Outcome of a First Stroke-like Episode in a Carrier of the Compound Heterozygous Variants c.695G_A and c.2209G_C in POLG: A Case Report.

Zieglgansberger D, Finsterer J Cureus. 2025; 17(2):e78428.

PMID: 40062103 PMC: 11885960. DOI: 10.7759/cureus.78428.


A perspective on human cell models for POLG-spectrum disorders: advantages and disadvantages of CRISPR-Cas-based vs. patient-derived iPSC models.

Cakmak C, Zempel H Med Genet. 2024; 33(3):245-249.

PMID: 38835703 PMC: 11006303. DOI: 10.1515/medgen-2021-2090.


Clinical Attributes and Electroencephalogram Analysis of Patients With Varying Alpers' Syndrome Genotypes.

Li H, Wang W, Han X, Zhang Y, Dai L, Xu M Front Pharmacol. 2021; 12:669516.

PMID: 34690748 PMC: 8526534. DOI: 10.3389/fphar.2021.669516.


POLG1-Related Epilepsy: Review of Diagnostic and Therapeutic Findings.

Specchio N, Pietrafusa N, Calabrese C, Trivisano M, Pepi C, De Palma L Brain Sci. 2020; 10(11).

PMID: 33113942 PMC: 7690674. DOI: 10.3390/brainsci10110768.


Dissecting the neuronal vulnerability underpinning Alpers' syndrome: a clinical and neuropathological study.

Hayhurst H, Anagnostou M, Bogle H, Grady J, Taylor R, Bindoff L Brain Pathol. 2018; 29(1):97-113.

PMID: 30021052 PMC: 7379503. DOI: 10.1111/bpa.12640.